Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Savolitinib - AstraZeneca/HUTCHMED

Next Previous
Drug Profile

Savolitinib - AstraZeneca/HUTCHMED

Alternative Names: AZD-6094; HMP-504; HMPL-504; Orpathys; Volitinib; Voressa

Latest Information Update: 02 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hutchison MediPharma
  • Developer AstraZeneca; Hutchison MediPharma; HUTCHMED; National Cancer Institute (USA); Samsung Medical Center
  • Class Antineoplastics; Imidazoles; Pyrazines; Pyrazoles; Pyridines; Small molecules; Triazoles
  • Mechanism of Action Proto-oncogene protein c-met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Preregistration Gastric cancer
  • Phase III Renal cell carcinoma
  • Phase II Colorectal cancer; Oesophageal cancer; Prostate cancer
  • No development reported CNS cancer; Solid tumours

Most Recent Events

  • 22 May 2026 Efficacy data from a phase II trial in Gastric Cancer and Oesophageal cancer released by HUTCHMED
  • 21 Apr 2026 Hutchison Medipharma completes a phase II trial in Gastric Cancer and Oesophageal cancer (Late-stage disease, Metastatic disease) (PO) (NCT04923932)
  • 31 Mar 2026 AstraZeneca terminates the phase-III SAMETA trial in Renal cell carcinoma (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Argentina, Australia, Brazil, Canada, Chile, China, Czechia, France, Germany, Hong Kong, India, Israel, Italy, Mexico, Netherlands, Poland, Romania, Singapore, South Korea, Spain, Taiwan, Turkey, Ukraine, UK, US (PO), due to lack of efficacy (NCT05043090) (AstraZeneca pipeline, May 2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top